Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

T Cell Activation and Clonal Selection01:22

T Cell Activation and Clonal Selection

3.4K
T cells are integral to our adaptive immune system, recognizing and effectively responding to foreign antigens. T cell activation and clonal selection are pivotal in orchestrating this immune response. This article elucidates these mechanisms, detailing the roles of cluster of differentiation (CD) markers, major histocompatibility complex (MHC) molecules, costimulatory signals, and the process of clonal selection.
Naive T cells that have not yet encountered an antigen express two primary CD...
3.4K
Cell-mediated Immune Responses01:40

Cell-mediated Immune Responses

70.4K
Overview
70.4K
Tumor Immunotherapy01:27

Tumor Immunotherapy

646
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
646
B Cell Activation and Differentiation01:24

B Cell Activation and Differentiation

4.4K
The adaptive immune response, a sophisticated defense mechanism, relies on the activation and differentiation of B lymphocytes, or B cells. These processes enable our bodies to mount a tailored response against specific pathogens such as bacteria, free virus particles, toxins, and parasites.
When naive B cells encounter a specific antigen that can bind to the B cell receptor (BCR) on their surface, they undergo sensitization to respond to the antigen's presence. Sensitization begins with...
4.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Pan-cancer single-cell atlases of mouse and human tumor-associated dendritic cells.

Nature communications·2026
Same author

Coordinate tumor-antigen uptake and dendritic cell activation by chimeric antigen receptors.

Science translational medicine·2025
Same author

Dendritic cell progenitors engineered to express extracellular-vesicle-internalizing receptors enhance cancer immunotherapy in mouse models.

Nature communications·2025
Same author

Harnessing deep learning to detect bronchiolitis obliterans syndrome from chest CT.

Communications medicine·2025
Same author

Human blood cell transcriptomics unveils dynamic systemic immune modulation along colorectal cancer progression.

Journal for immunotherapy of cancer·2024
Same author

Milestones in tumor vascularization and its therapeutic targeting.

Nature cancer·2024

Related Experiment Video

Updated: Sep 1, 2025

Tailoring In Vivo Cytotoxicity Assays to Study Immunodominance in Tumor-specific CD8+ T Cell Responses
10:13

Tailoring In Vivo Cytotoxicity Assays to Study Immunodominance in Tumor-specific CD8+ T Cell Responses

Published on: May 6, 2019

9.1K

Dendritic cell cross-dressing and tumor immunity.

Amaia Martinez-Usatorre1,2,3, Michele De Palma1,2,3

  • 1Swiss Institute for Experimental Cancer Research (ISREC), School of Life Sciences, Swiss Federal Institute of Technology in Lausanne (EPFL), Lausanne, Switzerland.

EMBO Molecular Medicine
|August 12, 2022
PubMed
Summary

Dendritic cells (DCs) can acquire preformed tumor antigen peptide-MHC complexes from cancer cells through cross-dressing. This mechanism is crucial for effective anti-tumor immunity and can be enhanced for therapeutic benefit.

More Related Videos

Preparation of Tumor Antigen-loaded Mature Dendritic Cells for Immunotherapy
08:40

Preparation of Tumor Antigen-loaded Mature Dendritic Cells for Immunotherapy

Published on: August 1, 2013

18.4K
Isolation Protocol of Mouse Monocyte-derived Dendritic Cells and Their Subsequent In Vitro Activation with Tumor Immune Complexes
11:48

Isolation Protocol of Mouse Monocyte-derived Dendritic Cells and Their Subsequent In Vitro Activation with Tumor Immune Complexes

Published on: May 31, 2018

11.5K

Related Experiment Videos

Last Updated: Sep 1, 2025

Tailoring In Vivo Cytotoxicity Assays to Study Immunodominance in Tumor-specific CD8+ T Cell Responses
10:13

Tailoring In Vivo Cytotoxicity Assays to Study Immunodominance in Tumor-specific CD8+ T Cell Responses

Published on: May 6, 2019

9.1K
Preparation of Tumor Antigen-loaded Mature Dendritic Cells for Immunotherapy
08:40

Preparation of Tumor Antigen-loaded Mature Dendritic Cells for Immunotherapy

Published on: August 1, 2013

18.4K
Isolation Protocol of Mouse Monocyte-derived Dendritic Cells and Their Subsequent In Vitro Activation with Tumor Immune Complexes
11:48

Isolation Protocol of Mouse Monocyte-derived Dendritic Cells and Their Subsequent In Vitro Activation with Tumor Immune Complexes

Published on: May 31, 2018

11.5K

Area of Science:

  • Immunology
  • Cancer Biology
  • Cellular Mechanisms

Background:

  • Dendritic cells (DCs) present antigens to T cells via direct, cross-presentation, and cross-dressing.
  • DC cross-dressing involves acquiring preformed peptide-MHC complexes from cancer cells.
  • This process is poorly understood but vital for anti-tumor immunity.

Purpose of the Study:

  • To elucidate the mechanism of DC cross-dressing.
  • To explore its role in anti-tumor immunity.
  • To investigate its potential for therapeutic enhancement.

Main Methods:

  • Documented DC cross-dressing in cell culture and tumor models.
  • Investigated mechanisms including uptake of extracellular vesicles and plasma membrane transfer.
  • Explored enhancement through DC engineering.

Main Results:

  • DC cross-dressing involves acquiring preformed peptide-MHC complexes from cancer cells.
  • Mechanisms include vesicle uptake and membrane fragment transfer.
  • Enhanced cross-dressing shows therapeutic potential.

Conclusions:

  • DC cross-dressing is a significant pathway for antigen presentation.
  • It is essential for productive anti-tumor immunity.
  • Engineering DCs for enhanced cross-dressing offers therapeutic promise.